Wyeth files Prevnar-13 in US while GSK's rival vaccine gains EU approval
This article was originally published in Scrip
Wyeth has filed a BLA with the US FDA for its 13-valent conjugated pneumococcal vaccine, Prevnar-13, for the prevention of pneumococcal diseases in infants and small children.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.